David W Dowdy

List of Publications by Year
in descending order

269 papers	11,972 citations	41258 49 h-index	32761 100 g-index
280 all docs	280 docs citations	280 times ranked	13989 citing authors

#	Article	IF	Citations
1	Conditional Cash Transfers to Incentivize Tuberculosis Screening: Description of a Novel Strategy for Contact Investigation in Rural South Africa. Clinical Infectious Diseases, 2022, 74, 957-964.	2.9	1
2	Effect of reductions in opioid prescribing on opioid use disorder and fatal overdose in the United States: a dynamic Markov model. Addiction, 2022, 117, 969-976.	1.7	7
3	The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease. Epidemiology, 2022, 33, 75-83.	1.2	2
4	Potential Effects of the Coronavirus Disease 2019 (COVID-19) Pandemic on Human Immunodeficiency Virus (HIV) Transmission: A Modeling Study in 32 US Cities. Clinical Infectious Diseases, 2022, 75, e1145-e1153.	2.9	6
5	Cost and Cost-Effectiveness of a Digital Adherence Technology for Tuberculosis Treatment Support in Uganda. Value in Health, 2022, 25, 924-930.	0.1	8
6	Disadvantage and the experience of treatment for multidrug-resistant tuberculosis (MDR-TB). SSM Qualitative Research in Health, 2022, 2, 100042.	0.6	1
7	Has the COVID-19 pandemic increased tuberculosis mortality?. Lancet Infectious Diseases, The, 2022, 22, 165-166.	4.6	4
8	Model-based Analysis of Tuberculosis Genotype Clusters in the United States Reveals High Degree of Heterogeneity in Transmission and State-level Differences Across California, Florida, New York, and Texas. Clinical Infectious Diseases, 2022, 75, 1433-1441.	2.9	2
9	Healthâ€related quality of life of female sex workers living with HIV in South Africa: a crossâ€sectional study. Journal of the International AIDS Society, 2022, 25, e25884.	1.2	4
10	Cost-effectiveness analysis of human-centred design for global health interventions: a quantitative framework. BMJ Global Health, 2022, 7, e007912.	2.0	5
11	A cost analysis of implementing mobile health facilitated tuberculosis contact investigation in a low-income setting. PLoS ONE, 2022, 17, e0265033.	1.1	6
12	â€œI refused to drink but they still forced meâ€: A mixed-methods approach to understanding the pathways to reduce alcohol use among Vietnamese people with HIV. Social Science and Medicine, 2022, 301, 114902.	1.8	2
13	Tuberculosis screening improves preventive therapy uptake (TB SCRIPT) trial among people living with HIV in Uganda: a study protocol of an individual randomized controlled trial. Trials, 2022, 23, 399.	0.7	2
14	Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings?. Lancet Infectious Diseases, The, 2022, 22, e271-e278.	4.6	28
15	Modeling to inform economyâ€wide pandemic policy: Bringing epidemiologists and economists together. Health Economics (United Kingdom), 2022, 31, 1291-1295.	0.8	3
16	Model-based Cost-effectiveness of State-level Latent Tuberculosis Interventions in California, Florida, New York, and Texas. Clinical Infectious Diseases, 2021, 73, e3476-e3482.	2.9	20
17	The Epidemiological Importance of Subclinical Tuberculosis. A Critical Reappraisal. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 168-174.	2.5	87
18	Cost-effectiveness of scaling up short course preventive therapy for tuberculosis among children across 12 countries. EClinicalMedicine, 2021, 31, 100707.	3.2	14

#	Article	IF	Citations
19	The Cost-Effectiveness of Adapting and Implementing a Brief Intervention to Target Frequent Alcohol Use Among Persons with HIV in Vietnam. AIDS and Behavior, 2021, 25, 2108-2119.	1.4	7
20	Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda. PLoS ONE, 2021, 16, e0246113.	1.1	8
21	Incorporating patient reporting patterns to evaluate spatially targeted TB interventions. Annals of Epidemiology, 2021, 54, 7-10.	0.9	2
22	Effectiveness of low-dose theophylline for the management of biomass-associated COPD (LODOT-BCOPD): study protocol for a randomized controlled trial. Trials, 2021, 22, 213.	0.7	4
23	Quantifying the potential value of antigen-detection rapid diagnostic tests for COVID-19: a modelling analysis. BMC Medicine, 2021, 19, 75.	2.3	40
24	Evaluating the effects of two alcohol reduction counseling interventions on intimate partner violence perpetration: secondary analysis of a threeâ€arm randomized controlled trial among Vietnamese men with HIV. Addiction, 2021, 116, 2712-2723.	1.7	3
25	Characterization of geographic mobility among participants in facility- and community-based tuberculosis case finding in urban Uganda. PLoS ONE, 2021, 16, e0251806.	1.1	6
26	Cost-effectiveness of universal HIV testing and treatment: where next?. The Lancet Global Health, 2021, 9, e573-e574.	2.9	1
27	Reply to Pierce: Subclinical Tuberculosis: Some Flies in the Ointment. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1328-1329.	2.5	1
28	Digital adherence technology for tuberculosis treatment supervision: AÂstepped-wedge cluster-randomized trialÂin Uganda. PLoS Medicine, 2021, 18, e1003628.	3.9	31
29	The longitudinal association between depression, anxiety symptoms and HIV outcomes, and the modifying effect of alcohol dependence among ART clients with hazardous alcohol use in Vietnam. Journal of the International AIDS Society, 2021, 24, e25746.	1.2	8
30	Design and execution of a public randomization ceremony to enhance stakeholder engagement within a cluster randomized trial to improve tuberculosis diagnosis in Uganda. Contemporary Clinical Trials Communications, 2021, 22, 100707.	0.5	1
31	Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Ugandaâ€"patient and health worker perspectives. Implementation Science Communications, 2021, 2, 71.	0.8	6
32	Refocusing the timeline of tuberculosis through the lens of BCG. Thorax, 2021, 76, thoraxjnl-2021-217289.	2.7	0
33	Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2021, 24, 100262.	0.6	3
34	Validating novel diagnostic assays for tuberculosis in the context of existing tools. The Lancet Global Health, 2021, 9, e1209.	2.9	4
35	What Will It Take to End HIV in the United States?. Annals of Internal Medicine, 2021, 174, 1542-1553.	2.0	12
36	Costs and cost-effectiveness of a comprehensive tuberculosis case finding strategy in Zambia. PLoS ONE, 2021, 16, e0256531.	1.1	13

#	Article	IF	Citations
37	Quantifying geographic heterogeneity in TB incidence and the potential impact of geographically targeted interventions in South and North City Corporations of Dhaka, Bangladesh: a model-based study. Epidemiology and Infection, 2021, 149, e106.	1.0	5
38	Sub-district level correlation between tuberculosis notifications and socio-demographic factors in Dhaka City corporation, Bangladesh. Epidemiology and Infection, 2021, 149, .	1.0	3
39	The Spectrum of Tuberculosis Disease in an Urban Ugandan Community and Its Health Facilities. Clinical Infectious Diseases, 2021, 72, e1035-e1043.	2.9	24
40	Achieving a â€œstep changeâ€•in the tuberculosis epidemic through comprehensive community-wide intervention: a model-based analysis. BMC Medicine, 2021, 19, 244.	2.3	9
41	Evidence-based COVID-19 policy-making in schools. Nature Medicine, 2021, 27, 2078-2079.	15.2	7
42	CKD and Risk of Incident Hospitalization With Clostridioides Difficile Infection: Findings From the Atherosclerosis Risk in Communities (ARIC) Study. American Journal of Kidney Diseases, 2021, , .	2.1	0
43	Completion of isoniazidâ€“rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectivenessâ€“implementation randomized trial. PLoS Medicine, 2021, 18, e1003875.	3.9	6
44	Multicomponent Strategy with Decentralized Molecular Testing for Tuberculosis. New England Journal of Medicine, 2021, 385, 2441-2450.	13.9	13
45	Aminoglycoside-induced Hearing Loss Among Patients Being Treated for Drug-resistant Tuberculosis in South Africa: A Prediction Model. Clinical Infectious Diseases, 2020, 70, 917-924.	2.9	14
46	Reply to Chen, Song, and Liu. Clinical Infectious Diseases, 2020, 70, 547-548.	2.9	0
47	Comparative Modeling of Tuberculosis Epidemiology and Policy Outcomes in California. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 356-365.	2.5	13
48	Clinical Impact of Rapid Drug Susceptibility Testing to Accompany Fluoroquinolone-Containing Universal Tuberculosis Regimens: A Markov Model. Clinical Infectious Diseases, 2020, 71, 2889-2896.	2.9	1
49	Costâ€effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda. Journal of the International AIDS Society, 2020, 23, e25623.	1.2	6
50	Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US. JAMA Network Open, 2020, 3, e2023677.	2.8	24
51	Towards evidenceâ€based integration of services for HIV, nonâ€communicable diseases and substance use: insights from modelling. Journal of the International AIDS Society, 2020, 23, e25525.	1.2	7
52	The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. EClinicalMedicine, 2020, 28, 100603.	3.2	203
53	Costing the implementation of public health interventions in resource-limited settings: a conceptual framework. Implementation Science, 2020, 15, 86.	2.5	43
54	Costâ€effectiveness of a 12 countryâ€intervention to scale up short course TB preventive therapy among people living with HIV. Journal of the International AIDS Society, 2020, 23, e25629.	1.2	4

#	Article	IF	Citations
55	Policy Implications of Mathematical Modeling of Latent Tuberculosis Infection Testing and Treatment Strategies to Accelerate Tuberculosis Elimination. Public Health Reports, 2020, 135, 38S-43S.	1.3	2
56	Implementation of two alcohol reduction interventions among persons with hazardous alcohol use who are living with HIV in Thai Nguyen, Vietnam: a micro-costing analysis. Global Health Action, 2020, 13, 1814035.	0.7	7
57	Comparing a standard and tailored approach to scaling up an evidence-based intervention for antiretroviral therapy for people who inject drugs in Vietnam: study protocol for a cluster randomized hybrid type III trial. Implementation Science, 2020, 15, 64.	2.5	5
58	Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implementation Science, 2020, 15, 65.	2.5	8
59	Effect of 2 Integrated Interventions on Alcohol Abstinence and Viral Suppression Among Vietnamese Adults With Hazardous Alcohol Use and HIV. JAMA Network Open, 2020, 3, e2017115.	2.8	24
60	Measuring Stigma to Assess the Social Justice Implications of Health-Related Policy Decisions: Application to Novel Treatment Regimens for Multidrug-Resistant Tuberculosis. MDM Policy and Practice, 2020, 5, 238146832091523.	0.5	4
61	The public health response to COVID-19: balancing precaution and unintended consequences. Annals of Epidemiology, 2020, 46, 12-13.	0.9	24
62	Is distance associated with tuberculosis treatment outcomes? A retrospective cohort study in Kampala, Uganda. BMC Infectious Diseases, 2020, 20, 406.	1.3	13
63	Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial. BMJ Open, 2020, 10, e033945.	0.8	33
64	Longitudinal analysis of alcohol use and intimate partner violence perpetration among men with HIV in northern Vietnam. Drug and Alcohol Dependence, 2020, 213, 108098.	1.6	1
65	Integrated screening and treatment services for HIV, hypertension and diabetes in Kenya: assessing the epidemiological impact and costâ€effectiveness from a national and regional perspective. Journal of the International AIDS Society, 2020, 23, e25499.	1.2	13
66	The urgent need to improve clinical practice guidelines for pediatric tuberculosis. International Journal of Tuberculosis and Lung Disease, 2020, 24, 264-264.	0.6	0
67	Challenges with scale-up of GeneXpert MTB/RIFÂ® in Uganda: a health systems perspective. BMC Health Services Research, 2020, 20, 162.	0.9	23
68	Spatial distribution of people diagnosed with tuberculosis through routine and active case finding: a community-based study in Kampala, Uganda. Infectious Diseases of Poverty, 2020, 9, 73.	1.5	9
69	Patientâ€incurred cost of inpatient treatment for Tuberculosis in rural Malawi. Tropical Medicine and International Health, 2020, 25, 624-634.	1.0	4
70	Redefining and revisiting cost estimates of routine ART care in Zambia: an analysis of ten clinics. Journal of the International AIDS Society, 2020, 23, e25431.	1.2	6
71	Study protocol: a cluster randomized trial to evaluate the effectiveness and implementation of onsite GeneXpert testing at community health centers in Uganda (XPEL-TB). Implementation Science, 2020, 15, 24.	2.5	14
72	Study protocol and implementation details for a pragmatic, stepped-wedge cluster randomised trial of a digital adherence technology to facilitate tuberculosis treatment completion. BMJ Open, 2020, 10, e039895.	0.8	11

#	Article	IF	Citations
73	A clinical score for identifying active tuberculosis while awaiting microbiological results: Development and validation of a multivariable prediction model in sub-Saharan Africa. PLoS Medicine, 2020, 17, e1003420.	3.9	13
74	Alcohol abstinence stigma and alcohol use among HIV patients in Thai Nguyen, Vietnam. PLoS ONE, 2020, 15, e0239330.	1.1	8
75	The Relationship of COVID-19 Severity with Cardiovascular Disease and Its Traditional Risk Factors: A Systematic Review and Meta-Analysis. Global Heart, 2020, 15, 64.	0.9	115
76	Prevalence of Pre-Existing Hearing Loss Among Patients With Drug-Resistant Tuberculosis in South Africa. American Journal of Audiology, 2020, 29, 199-205.	0.5	5
77	Assessing the Impact of Targeted Screening and Treatment of Diabetes and Hypertension Among Adults Living with HIV in Nairobi, Kenya. , 2020, , .		1
78	Evaluation of underweight status may improve identification of the highest-risk patients during outpatient evaluation for pulmonary tuberculosis. PLoS ONE, 2020, 15, e0243542.	1.1	2
79	Brief Report: Proportion and Predictors of Adult TB Contacts Accepting HIV Testing During an Active TB Case Finding Intervention in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 525-529.	0.9	0
80	Alcohol use, depressive symptoms, and intimate partner violence perpetration: A longitudinal analysis among men with HIV in northern Vietnam. PLoS ONE, 2020, 15, e0240674.	1.1	0
81	Title is missing!. , 2020, 17, e1003420.		0
82	Title is missing!. , 2020, 17, e1003420.		0
83	Title is missing!. , 2020, 17, e1003420.		0
84	Title is missing!. , 2020, 17, e1003420.		0
85	Title is missing!. , 2020, 17, e1003420.		0
86	Title is missing!. , 2020, 15, e0243542.		0
87	Title is missing!. , 2020, 15, e0243542.		0
88	Title is missing!. , 2020, 15, e0243542.		0
89	Title is missing!. , 2020, 15, e0243542.		0
90	What if They Donâ€™t Have Tuberculosis? The Consequences and Trade-offs Involved in False-positive Diagnoses of Tuberculosis. Clinical Infectious Diseases, 2019, 68, 150-156.	2.9	24

#	Article	IF	Citations
91	Screening for Tuberculosis With Xpert MTB/RIF Assay Versus Fluorescent Microscopy Among Adults Newly Diagnosed With Human Immunodeficiency Virus in Rural Malawi: A Cluster Randomized Trial (Chepetsa). Clinical Infectious Diseases, 2019, 68, 1176-1183.	2.9	21
92	Informing decision-making for universal access to quality tuberculosis diagnosis in India: an economic-epidemiological model. BMC Medicine, 2019, 17, 155.	2.3	19
93	Empiric treatment of pulmonary TB in the Xpert era: Correspondence of sputum culture, Xpert MTB/RIF, and clinical diagnoses. PLoS ONE, 2019, 14, e0220251.	1.1	20
94	Impact and Effectiveness of State-Level Tuberculosis Interventions in California, Florida, New York, and Texas: A Model-Based Analysis. American Journal of Epidemiology, 2019, 188, 1733-1741.	1.6	13
95	A Systematic Review to Evaluate the Association between Clean Cooking Technologies and Time Use in Low- and Middle-Income Countries. International Journal of Environmental Research and Public Health, 2019, 16, 2277.	1.2	26
96	The economic case for typhoid conjugate vaccines in countries with medium and high incidence of infection. Lancet Infectious Diseases, The, 2019, 19, 675-676.	4.6	2
97	Ending the Human Immunodeficiency Virus Epidemic: Towards an Evidence-Based Approach. Clinical Infectious Diseases, 2019, 69, 2199-2200.	2.9	1
98	Guidance for Studies Evaluating the Accuracy of Tuberculosis Triage Tests. Journal of Infectious Diseases, 2019, 220, S116-S125.	1.9	33
99	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respiratory Medicine,the, 2019, 7, 820-826.	5.2	92
100	Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations. BMC Infectious Diseases, 2019, 19, 794.	1.3	6
101	Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration. American Journal of Epidemiology, 2019, 188, 2078-2085.	1.6	20
102	Siyaphambili protocol: An evaluation of randomized, nurseâ€led adaptive HIV treatment interventions for cisgender female sex workers living with HIV in Durban, South Africa. Research in Nursing and Health, 2019, 42, 107-118.	0.8	18
103	Quality of care for patients evaluated for tuberculosis in the context of Xpert MTB/RIF scale-up. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2019, 15, 100099.	0.6	6
104	Treatment of latent infection to achieve tuberculosis elimination in low-incidence countries. PLoS Medicine, 2019, 16, e1002824.	3.9	27
105	Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation. The Lancet Global Health, 2019, 7, e798-e807.	2.9	33
106	Operational characteristics of antiretroviral therapy clinics in Zambia: a time and motion analysis. BMC Health Services Research, 2019, 19, 244.	0.9	11
107	Contact tracing versus facility-based screening for active TB case finding in rural South Africa: A pragmatic cluster-randomized trial (Kharitode TB). PLoS Medicine, 2019, 16, e1002796.	3.9	36
108	Gonorrhoea and chlamydia diagnosis as an entry point for HIV pre-exposure prophylaxis: a modelling study. BMJ Open, 2019, 9, e023453.	0.8	5

#	Article	IF	Citations
109	Screening for tuberculosis: time to move beyond symptoms. Lancet Respiratory Medicine,the, 2019, 7, 202-204.	5.2	22
110	From Epidemiologic Knowledge to Improved Health: A Vision for Translational Epidemiology. American Journal of Epidemiology, 2019, 188, 2049-2060.	1.6	10
111	Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting. Aids, 2019, 33, 525-536.	1.0	7
112	Clinical Consequences of Using an Indeterminate Range for Early Infant Diagnosis of HIV: A Decision Model. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 287-296.	0.9	1
113	Differentiated Care Preferences of Stable Patients on Antiretroviral Therapy in Zambia: A Discrete Choice Experiment. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 540-546.	0.9	58
114	Projecting the impact of variable MDR-TB transmission efficiency on long-term epidemic trends in South Africa and Vietnam. Scientific Reports, 2019, 9, 18099.	1.6	4
115	Yield and Efficiency of Novel Intensified Tuberculosis Case-Finding Algorithms for People Living with HIV. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 643-650.	2.5	36
116	Spatially targeted screening to reduce tuberculosis transmission in high-incidence settings. Lancet Infectious Diseases, The, 2019, 19, e89-e95.	4.6	41
117	The Importance of Heterogeneity to the Epidemiology of Tuberculosis. Clinical Infectious Diseases, 2019, 69, 159-166.	2.9	68
118	Maternal Motivation to Take Preventive Therapy in Antepartum and Postpartum Among HIV-Positive Pregnant Women in South Africa: A Choice Experiment. AIDS and Behavior, 2019, 23, 1689-1697.	1.4	8
119	Integrating social justice concerns into economic evaluation for healthcare and public health: A systematic review. Social Science and Medicine, 2018, 198, 27-35.	1.8	34
120	Brief Report: â€œGive Me Some Timeâ€• Facilitators of and Barriers to Uptake of Home-Based HIV Testing During Household Contact Investigation for Tuberculosis in Kampala, Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 400-404.	0.9	10
121	The effect of partner HIV status on motivation to take antiretroviral and isoniazid preventive therapies: a conjoint analysis. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1298-1305.	0.6	5
122	Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings. Clinical Infectious Diseases, 2018, 67, 1072-1078.	2.9	43
123	Impact of Providing Preexposure Prophylaxis for Human Immunodeficiency Virus at Clinics for Sexually Transmitted Infections in Baltimore City: An Agent-based Model. Sexually Transmitted Diseases, 2018, 45, 791-797.	0.8	11
124	Simple Inclusion of Complex Diagnostic Algorithms in Infectious Disease Models for Economic Evaluation. Medical Decision Making, 2018, 38, 930-941.	1.2	1
125	Tuberculosis Incidence Among Populations at High Risk in California, Florida, New York, and Texas, 2011â€“2015. American Journal of Public Health, 2018, 108, S311-S314.	1.5	5
126	Economic and epidemiologic impact of guidelines for early ART initiation irrespective of CD4 count in Spain. PLoS ONE, 2018, 13, e0206755.	1.1	11

#	Article	IF	Citations
127	Would pan-tuberculosis treatment regimens be cost-effective?. Lancet Respiratory Medicine,the, 2018, 6, 486-488.	5.2	5
128	Maternal priorities for preventive therapy among <scp>HIV</scp>â€positive pregnant women before and after delivery in South Africa: aÂbestâ€“worst scaling survey. Journal of the International AIDS Society, 2018, 21, e25143.	1.2	11
129	Yield of household contact tracing for tuberculosis in rural South Africa. BMC Infectious Diseases, 2018, 18, 299.	1.3	31
130	Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clinical Microbiology Reviews, 2018, 31, .	5.7	353
131	Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Societyâ€”Lancet Commission. Lancet, The, 2018, 392, 312-358.	6.3	230
132	Chest X-ray for tuberculosis preventive therapy: use caution. Lancet HIV,the, 2018, 5, e478-e479.	2.1	2
133	What Will It Take to Reduce HIV Incidence in the United States: A Mathematical Modeling Analysis. Open Forum Infectious Diseases, 2018, 5, ofy008.	0.4	6
134	Minding the Gap: Specimen Referral Systems for Diagnosis of Infectious Diseases. Clinical Infectious Diseases, 2017, 64, ciw820.	2.9	5
135	Multidrug-resistant tuberculosis in India: looking back, thinking ahead. Lancet Public Health, The, 2017, 2, e8-e9.	4.7	2
136	Identifying barriers to and facilitators of tuberculosis contact investigation in Kampala, Uganda: a behavioral approach. Implementation Science, 2017, 12, 33.	2.5	77
137	Challenges in the Evaluation of Interventions to Improve Engagement Along the HIV Care Continuum in the United States: A Systematic Review. AIDS and Behavior, 2017, 21, 2101-2123.	1.4	44
138	Cost-effectiveness of Diagnostic Algorithms for Tuberculosis in Children Less Than 5 Years of Age. Pediatric Infectious Disease Journal, 2017, 36, 36-43.	1.1	12
139	Comparing Drivers and Dynamics of Tuberculosis in California, Florida, New York, and Texas. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1050-1059.	2.5	25
140	Of Testing and Treatment: Implications of Implementing New Regimens for Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases, 2017, 65, 1206-1211.	2.9	13
141	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respiratory Medicine,the, 2017, 5, 291-360.	5.2	459
142	Drug-resistant tuberculosis in 2017: at a crossroads. Lancet Respiratory Medicine,the, 2017, 5, 241-242.	5.2	6
143	Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis. Lancet Respiratory Medicine,the, 2017, 5, 191-199.	5.2	23
144	Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. International Journal of Infectious Diseases, 2017, 56, 185-189.	1.5	14

#	Article	IF	Citations
145	A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	17
146	Mathematical Modeling of â€œChronicâ€•Infectious Diseases: Unpacking the Black Box. Open Forum Infectious Diseases, 2017, 4, ofx172.	0.4	12
147	Point-of-care C-reactive protein-based tuberculosis screening for people living with HIV: a diagnostic accuracy study. Lancet Infectious Diseases, The, 2017, 17, 1285-1292.	4.6	96
148	Current and future trends in tuberculosis incidence in New York City: a dynamic modelling analysis. Lancet Public Health, The, 2017, 2, e323-e330.	4.7	12
149	Improving active case finding for tuberculosis in South Africa: informing innovative implementation approaches in the context of the Kharitode trial through formative research. Health Research Policy and Systems, 2017, 15, 42.	1.1	22
150	Research Roadmap for Tuberculosis Transmission Science: Where Do We Go From Here and How Will We Know When Weâ€™re There?. Journal of Infectious Diseases, 2017, 216, S662-S668.	1.9	17
151	What We Know About Tuberculosis Transmission: An Overview. Journal of Infectious Diseases, 2017, 216, S629-S635.	1.9	193
152	Impact of Targeted Tuberculosis Vaccination Among a Mining Population in South Africa: A Model-Based Study. American Journal of Epidemiology, 2017, 186, 1362-1369.	1.6	13
153	Designing and Evaluating Interventions to Halt the Transmission of Tuberculosis. Journal of Infectious Diseases, 2017, 216, S654-S661.	1.9	26
154	Optimal costs of HIV pre-exposure prophylaxis for men who have sex with men. PLoS ONE, 2017, 12, e0178170.	1.1	25
155	Estimated clinical impact of the Xpert MTB/RIF Ultra cartridge for diagnosis of pulmonary tuberculosis: A modeling study. PLoS Medicine, 2017, 14, e1002472.	3.9	50
156	Measuring success: The challenge of social protection in helping eliminate tuberculosis. PLoS Medicine, 2017, 14, e1002419.	3.9	0
157	Describing the global burden of MDR-TB: missing cases or different metrics?. International Journal of Tuberculosis and Lung Disease, 2017, 21, 1-1.	0.6	0
158	Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. PLoS Medicine, 2017, 14, e1002202.	3.9	20
159	MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis. PLoS ONE, 2017, 12, e0172748.	1.1	30
160	Drop-out from the tuberculosis contact investigation cascade in a routine public health setting in urban Uganda: A prospective, multi-center study. PLoS ONE, 2017, 12, e0187145.	1.1	35
161	Cost-effectiveness of triage testing for facility-based systematic screening of tuberculosis among Ugandan adults. BMJ Global Health, 2016, 1, e000064.	2.0	7
162	Potential impact of spatially targeted adult tuberculosis vaccine in Gujarat, India. Journal of the Royal Society Interface, 2016, 13, 20151016.	1.5	18

#	Article	IF	Citations
163	Effect of the US National HIV/AIDS Strategy targets for improved HIV care engagement: a modelling study. Lancet HIV,the, 2016, 3, e140-e146.	2.1	42
164	Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. The Lancet Global Health, 2016, 4, e806-e815.	2.9	138
165	Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. The Lancet Global Health, 2016, 4, e816-e826.	2.9	69
166	Serial testing for latent tuberculosis using QuantiFERON-TB Gold In-Tube: A Markov model. Scientific Reports, 2016, 6, 30781.	1.6	27
167	Tuberculosis. Nature Reviews Disease Primers, 2016, 2, 16076.	18.1	830
168	Implementation of Xpert MTB/RIF in Uganda: Missed Opportunities to Improve Diagnosis of Tuberculosis. Open Forum Infectious Diseases, 2016, 3, ofw068.	0.4	42
169	Ancient Disease, Modern Epidemiology: A Century of Progress in Understanding and Fighting Tuberculosis. American Journal of Epidemiology, 2016, 183, 407-414.	1.6	9
170	Bridging the gap between evidence and policy for infectious diseases: How models can aid public health decision-making. International Journal of Infectious Diseases, 2016, 42, 17-23.	1.5	54
171	The Epidemiologic and Economic Impact of Improving HIV Testing, Linkage, and Retention in Care in the United States. Clinical Infectious Diseases, 2016, 62, 220-229.	2.9	79
172	How Do Urban Indian Private Practitioners Diagnose and Treat Tuberculosis? A Cross-Sectional Study in Chennai. PLoS ONE, 2016, 11, e0149862.	1.1	17
173	Cost-Effectiveness of Automated Digital Microscopy for Diagnosis of Active Tuberculosis. PLoS ONE, 2016, 11, e0157554.	1.1	9
174	Use of Rapid, Point-of-Care Assays by Private Practitioners in Chennai, India: Priorities for Tuberculosis Diagnostic Testing. PLoS ONE, 2016, 11, e0155775.	1.1	1
175	Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis. Annals of Internal Medicine, 2015, 163, 32-39.	2.0	91
176	Evaluating the cost of adult voluntary medical male circumcision in a mixed (surgical and PrePex) site compared to a hypothetical PrePex-only site in South Africa. Global Health Action, 2015, 8, 29116.	0.7	5
177	Screening for Tuberculosis Among Adults Newly Diagnosed With HIV in Sub-Saharan Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 83-90.	0.9	17
178	Reducing relapse in tuberculosis treatment: is it time to reassess WHO treatment guidelines?. International Journal of Tuberculosis and Lung Disease, 2015, 19, 624-624.	0.6	10
179	In reply. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1264-1264.	0.6	0
180	C-Reactive Protein (CRP), Interferon Gamma-Inducible Protein 10 (IP-10), and Lipopolysaccharide (LPS) Are Associated with Risk of Tuberculosis after Initiation of Antiretroviral Therapy in Resource-Limited Settings. PLoS ONE, 2015, 10, e0117424.	1.1	23

#	Article	IF	Citations
181	A Novel Tool Improves Existing Estimates of Recent Tuberculosis Transmission in Settings of Sparse Data Collection. PLoS ONE, 2015, 10, e0144137.	1.1	7
182	The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa. PLoS ONE, 2015, 10, e0145796.	1.1	10
183	Mathematical Modelling and Tuberculosis: Advances in Diagnostics and Novel Therapies. Advances in Medicine, 2015, 2015, 1-10.	0.3	24
184	Economic and epidemiological impact of early antiretroviral therapy initiation in India. Journal of the International AIDS Society, 2015, 18, 20217.	1.2	13
185	Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Nature, 2015, 528, S68-S76.	13.7	141
186	Understanding the incremental value of novel diagnostic tests for tuberculosis. Nature, 2015, 528, S60-S67.	13.7	114
187	Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respiratory Medicine,the, 2015, 3, 963-972.	5.2	165
188	Risk Factors for Delirium. Critical Care Medicine, 2015, 43, 232-233.	0.4	8
189	Performance of a Novel Algorithm Using Automated Digital Microscopy for Diagnosing Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1443-1449.	2.5	25
190	The Distribution of Fitness Costs of Resistance-Conferring Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis. Clinical Infectious Diseases, 2015, 61, S147-S154.	2.9	40
191	Stopping the body count: a comprehensive approach to move towards zero tuberculosis deaths. Lancet, The, 2015, 386, e46-e47.	6.3	48
192	Data for action: collection and use of local data to end tuberculosis. Lancet, The, 2015, 386, 2324-2333.	6.3	89
193	Costs and Consequences of Using Interferon-Î³ Release Assays for the Diagnosis of Active Tuberculosis in India. PLoS ONE, 2015, 10, e0124525.	1.1	13
194	Do We Need to Detect Isoniazid Resistance in Addition to Rifampicin Resistance in Diagnostic Tests for Tuberculosis?. PLoS ONE, 2014, 9, e84197.	1.1	26
195	Population-Level Impact of Shorter-Course Regimens for Tuberculosis: A Model-Based Analysis. PLoS ONE, 2014, 9, e96389.	1.1	10
196	Clinical Effectiveness and Cost-Effectiveness of HIV Pre-Exposure Prophylaxis in Men Who Have Sex with Men: Risk Calculators for Real-World Decision-Making. PLoS ONE, 2014, 9, e108742.	1.1	53
197	Timing of Tuberculosis Transmission and the Impact of Household Contact Tracing. An Agent-based Simulation Model. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 845-852.	2.5	80
198	How much is tuberculosis screening worth? Estimating the value of active case finding for tuberculosis in South Africa, China, and India. BMC Medicine, 2014, 12, 216.	2.3	77

#	Article	IF	Citations
199	The Importance of Implementation Strategy in Scaling Up Xpert MTB/RIF for Diagnosis of Tuberculosis in the Indian Health-Care System: A Transmission Model. PLoS Medicine, 2014, 11, e1001674.	3.9	42
200	Estimating the proportion of tuberculosis recent transmission via simulation. , 2014, , .		4
201	The impact of novel tests for tuberculosis depends on the diagnostic cascade. European Respiratory Journal, 2014, 44, 1366-1369.	3.1	10
202	Bold thinking for bold results: modeling the elimination of tuberculosis. International Journal of Tuberculosis and Lung Disease, 2014, 18, 883-883.	0.6	1
203	Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials. Clinical Infectious Diseases, 2014, 58, 1297-1307.	2.9	293
204	Transforming the Fight Against Tuberculosis: Targeting Catalysts of Transmission. Clinical Infectious Diseases, 2014, 59, 1123-1129.	2.9	37
205	Physical Complications in Acute Lung Injury Survivors. Critical Care Medicine, 2014, 42, 849-859.	0.4	480
206	Impact of Isoniazid Preventive Therapy for HIV-Infected Adults in Rio de Janeiro, Brazil. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 552-558.	0.9	24
207	Healthy But Harmed. JAMA - Journal of the American Medical Association, 2014, 312, 1399.	3.8	0
208	Point-of-Care Tests for HIV, Related Coinfections, and Blood-Borne Infections. AIDS Research and Treatment, 2014, 2014, 1-2.	0.3	4
209	Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection. Clinical Microbiology Reviews, 2014, 27, 3-20.	5.7	662
210	Economic Evaluation of Laboratory Testing Strategies for Hospital-Associated Clostridium difficile Infection. Journal of Clinical Microbiology, 2014, 52, 489-496.	1.8	37
211	Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet, The, 2014, 383, 424-435.	6.3	379
212	Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis. Open Forum Infectious Diseases, 2014, 1, ofu073.	0.4	15
213	Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings?. Lancet Infectious Diseases, The, 2014, 14, 527-532.	4.6	141
214	Tuberculosis: progress and challenges in product development and delivery. Lancet Respiratory Medicine,the, 2014, 2, 25-27.	5.2	3
215	Modeling of Novel Diagnostic Strategies for Active Tuberculosis â€“ A Systematic Review: Current Practices and Recommendations. PLoS ONE, 2014, 9, e110558.	1.1	23
216	A user-friendly, open-source tool to project impact and cost of diagnostic tests for tuberculosis. ELife, 2014, 3, .	2.8	12

#	Article	IF	Citations
217	The eye of the beholder: tuberculosis screening for elderly long-term care residents [Editorial]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 1121-1121.	0.6	1
218	An agent-based simulation of a Tuberculosis epidemic: Understanding the timing of transmission. , 2013, , .		19
219	Severe mental illness at <scp>ART</scp> initiation is associated with worse retention in care among <scp>HIV</scp>â€infected <scp>U</scp>gandan adults. Tropical Medicine and International Health, 2013, 18, 53-57.	1.0	33
220	Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infectious Diseases, The, 2013, 13, 449-458.	4.6	59
221	Economic evaluations of point of care testing strategies for active tuberculosis. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 313-325.	0.7	5
222	Is Passive Diagnosis Enough?. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 543-551.	2.5	103
223	Setting clinical priorities: A framework for incorporating individual patient preferences. Patient Education and Counseling, 2013, 90, 141-143.	1.0	2
224	Challenges in Evaluating the Cost-effectiveness of New Diagnostic Tests for HIV-Associated Tuberculosis. Clinical Infectious Diseases, 2013, 57, 1021-1026.	2.9	14
225	Modeling the Impact of Alternative Strategies for Rapid Molecular Diagnosis of Tuberculosis in Southeast Asia. American Journal of Epidemiology, 2013, 178, 1740-1749.	1.6	31
226	Post-2015 tuberculosis strategies in a pre-2015 world [Editorial]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 143-143.	0.6	1
227	Population-Level Impact of Same-Day Microscopy and Xpert MTB/RIF for Tuberculosis Diagnosis in Africa. PLoS ONE, 2013, 8, e70485.	1.1	22
228	Rapid Molecular Testing for TB to Guide Respiratory Isolation in the U.S.: A Cost-Benefit Analysis. PLoS ONE, 2013, 8, e79669.	1.1	35
229	Latent Tuberculosis: Models, Computational Efforts and the Pathogenâ€™s Regulatory Mechanisms during Dormancy. Frontiers in Bioengineering and Biotechnology, 2013, 1, 4.	2.0	27
230	Population-Level Impact of Active Tuberculosis Case Finding in an Asian Megacity. PLoS ONE, 2013, 8, e77517.	1.1	28
231	The impact of new tuberculosis diagnostics on transmission: why context matters. Bulletin of the World Health Organization, 2012, 90, 739-747.	1.5	51
232	The Ethics of Testing a Test: Randomized Trials of the Health Impact of Diagnostic Tests for Infectious Diseases. Clinical Infectious Diseases, 2012, 55, 1522-1526.	2.9	14
233	Heterogeneity in tuberculosis transmission and the role of geographic hotspots in propagating epidemics. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9557-9562.	3.3	132
234	Rejoinder. Epidemiology, 2012, 23, 927-928.	1.2	1

#	Article	IF	Citations
235	Tuberculosis control in crisis: economic honesty and comparative effectiveness [Correspondence]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 1131-1132.	0.6	1
236	Bridging the Gap Between Knowledge and Health. Epidemiology, 2012, 23, 914-918.	1.2	9
237	Thinking outside the box. Critical Care Medicine, 2012, 40, 2231-2232.	0.4	3
238	A call to action for comprehensive HIV services for men who have sex with men. Lancet, The, 2012, 380, 424-438.	6.3	226
239	Tests for latent tuberculosis infection and isoniazid preventive therapy. Lancet Infectious Diseases, The, 2012, 12, 827-828.	4.6	2
240	Sudden Cardiac Death in Patients With Human Immunodeficiency Virus Infection. Journal of the American College of Cardiology, 2012, 59, 1891-1896.	1.2	228
241	Economic analyses of diagnostics for tuberculosis: whatâ€™s the point?. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 137-139.	0.7	3
242	Serological tests for the diagnosis of active tuberculosis: relevance for India. Indian Journal of Medical Research, 2012, 135, 695-702.	0.4	16
243	Patient Follow-up in an Urban Resident Continuity Clinic: An Initiative to Improve Scheduling Practices. Journal of Graduate Medical Education, 2011, 3, 256-260.	0.6	5
244	Mortality Among Antiretroviral-Eligible Patients in an Urban Public Clinic. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 297-300.	0.9	8
245	Trained to Avoid Primary Care. Annals of Internal Medicine, 2011, 154, 776.	2.0	5
246	Costâ€effectiveness of Targeted Human Immunodeficiency Virus Screening in an Urban Emergency Department. Academic Emergency Medicine, 2011, 18, 745-753.	0.8	23
247	Tobacco Smoking and Bladder Cancer. JAMA - Journal of the American Medical Association, 2011, 306, 2216.	3.8	6
248	Serological Testing Versus Other Strategies for Diagnosis of Active Tuberculosis in India: A Cost-Effectiveness Analysis. PLoS Medicine, 2011, 8, e1001074.	3.9	63
249	Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for Tuberculosis. PLoS Medicine, 2011, 8, e1001063.	3.9	56
250	Sensitivity of direct versus concentrated sputum smear microscopy in HIV-infected patients suspected of having pulmonary tuberculosis. BMC Infectious Diseases, 2009, 9, 53.	1.3	71
251	Are intensive care factors associated with depressive symptoms 6 months after acute lung injury?*. Critical Care Medicine, 2009, 37, 1702-1707.	0.4	77
252	The persistence of tuberculosis in the age of DOTS: reassessing the effect of case detection. Bulletin of the World Health Organization, 2009, 87, 296-304.	1.5	57

#	Article	IF	Citations
253	Impact of enhanced tuberculosis diagnosis in South Africa: A mathematical model of expanded culture and drug susceptibility testing. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 11293-11298.	3.3	87
254	Intensive care unit hypoglycemia predicts depression during early recovery from acute lung injury*. Critical Care Medicine, 2008, 36, 2726-2733.	0.4	78
255	Impact and Cost-Effectiveness of Culture for Diagnosis of Tuberculosis in HIV-Infected Brazilian Adults. PLoS ONE, 2008, 3, e4057.	1.1	44
256	Adherence to Nonnucleoside Reverse Transcriptase Inhibitorâ€“Based HIV Therapy and Virologic Outcomes. Annals of Internal Medicine, 2007, 146, 564.	2.0	318
257	Neuromuscular dysfunction acquired in critical illness: aÂsystematic review. Intensive Care Medicine, 2007, 33, 1876-1891.	3.9	527
258	The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model. Aids, 2006, 20, 751-762.	1.0	67
259	Quality of life after acute respiratory distress syndrome: aÂmeta-analysis. Intensive Care Medicine, 2006, 32, 1115-1124.	3.9	316
260	Country-wide distribution of the nitrile female condom (FC2) in Brazil and South Africa: a cost-effectiveness analysis. Aids, 2006, 20, 2091-2098.	1.0	33
261	Breaking the Translational Barriers: The Value of Integrating Biomedical Informatics and Translational Research. Journal of Investigative Medicine, 2005, 53, 192-200.	0.7	86
262	Quality of life in adult survivors of critical illness: A systematic review of the literature. Intensive Care Medicine, 2005, 31, 611-620.	3.9	460
263	Studying outcomes of intensive care unit survivors: measuring exposures and outcomes. Intensive Care Medicine, 2005, 31, 1153-1160.	3.9	54
264	Studying outcomes of intensive care unit survivors: the role of the cohort study. Intensive Care Medicine, 2005, 31, 914-921.	3.9	31
265	Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy. Clinical Pharmacology and Therapeutics, 2003, 73, 78-86.	2.3	22
266	Cost-Effectiveness Analysis of the Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test as Used Routinely on Smear-Positive Respiratory Specimens. Journal of Clinical Microbiology, 2003, 41, 948-953.	1.8	44
267	Improving the US Health Care System: Action Plan to Enhance Efficiency, Reduce Errors, and Improve Quality. Journal of Investigative Medicine, 2003, 51, 72-78.	0.7	3
268	Evaluation of Health Promotion and Disease Prevention Programs. Clinical Infectious Diseases, 0, , civ740.	2.9	0
269	Coughing is Not Required to Transmit Mycobacterium tuberculosis: Another Nail in the Coffin. American Journal of Respiratory and Critical Care Medicine, 0, , .	2.5	1